Cargando…

Survival in melanoma brain metastases in the era of novel systemic therapies

BACKGROUND: Melanoma brain metastases (MBMs) have historically poor overall survival (OS). Recently introduced systemic anticancer therapies (SACTs), namely targeted therapies such as BRAF inhibitors and immunotherapy, to control advanced disease have shown improved survival. Today, increasingly agg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Merola, Joseph P, Ocen, Joanita, Kumar, Satish, Powell, James, Hayhurst, Caroline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Clinical Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764504/ https://www.ncbi.nlm.nih.gov/pubmed/33392503 http://dx.doi.org/10.1093/noajnl/vdaa144

Ejemplares similares

Metastatic melanoma: prognostic factors and survival in patients with brain metastases
por: Frinton, E., et al.
Publicado: (2017)

Management of Melanoma Brain Metastases in the Era of Targeted Therapy
por: Shapiro, Daniela Gonsalves, et al.
Publicado: (2011)

Melanoma Brain Metastases in the Era of Target Therapies: An Overview
por: Becco, Paolo, et al.
Publicado: (2020)

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
por: Tawbi, Hussein A, et al.
Publicado: (2021)

Determinants of survival in patients with brain metastases from cutaneous melanoma
por: Staudt, M, et al.
Publicado: (2010)

Epidemiology of synchronous brain metastases
por: Singh, Raj, et al.
Publicado: (2020)

Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy
por: Rieth, John M., et al.
Publicado: (2021)

Stereotactic radiosurgery for melanoma brain metastases: dose-size response relationship in the era of immunotherapy
por: Yusuf, Mehran, et al.
Publicado: (2021)

Control and Toxicity in Melanoma Versus Other Brain Metastases in Response to Combined Radiosurgery and PD-(L)1 Immune Checkpoint Inhibition
por: Travis, Roman L., et al.
Publicado: (2020)

The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases
por: Fujita, Yuya, et al.
Publicado: (2020)

Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases
por: Berghoff, Anna Sophie, et al.
Publicado: (2020)

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases
por: Niessner, Heike, et al.
Publicado: (2013)

Ipilimumab and radiation therapy for melanoma brain metastases
por: Silk, Ann W, et al.
Publicado: (2013)

An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery—the BUMPER study
por: Amaral, Teresa, et al.
Publicado: (2020)

Changes in outcomes and factors associated with survival in melanoma patients with brain metastases
por: Hasanov, Merve, et al.
Publicado: (2022)

Changes in Health Care Costs, Survival, and Time Toxicity in the Era of Immunotherapy and Targeted Systemic Therapy for Melanoma
por: Bateni, Sarah B., et al.
Publicado: (2023)

Epidemiological trends, prognostic factors, and survival outcomes of synchronous brain metastases from 2015 to 2019: a population-based study
por: Parker, Megan, et al.
Publicado: (2023)

Efficacy of laser interstitial thermal therapy for biopsy-proven radiation necrosis in radiographically recurrent brain metastases
por: Chan, Michael, et al.
Publicado: (2023)

Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases
por: Weiss, Sarah A., et al.
Publicado: (2020)

PD-L1 expression in breast cancer brain metastases
por: Chehade, Rania, et al.
Publicado: (2022)

Subtype switching in breast cancer brain metastases: a multicenter analysis
por: Hulsbergen, Alexander F C, et al.
Publicado: (2020)

Combination laser interstitial thermal therapy plus stereotactic radiotherapy increases time to progression for biopsy-proven recurrent brain metastases
por: Grabowski, Matthew M, et al.
Publicado: (2022)

Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy
por: Vasudevan, Harish N., et al.
Publicado: (2023)

An integrated disease-specific graded prognostic assessment scale for melanoma: contributions of KPS, CITV, number of metastases, and BRAF mutation status
por: Ahluwalia, Manmeet, et al.
Publicado: (2020)

Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases
por: Wong, Philip, et al.
Publicado: (2023)

Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis
por: Tong, T. M. L., et al.
Publicado: (2022)

Responses in the diffusivity and vascular function of the irradiated normal brain are seen up until 18 months following SRS of brain metastases
por: Nilsen, Line Brennhaug, et al.
Publicado: (2020)

Outcome comparison of patients who develop leptomeningeal disease or distant brain recurrence after brain metastases resection cavity radiosurgery
por: Teyateeti, Achiraya, et al.
Publicado: (2021)

Stereotactic Radiofrequency Ablation of Breast Cancer Liver Metastases: Short- and Long-Term Results with Predicting Factors for Survival
por: Schullian, Peter, et al.
Publicado: (2021)

Evaluation of Safety and Dosimetry of (177)Lu-DOTA-ZOL for Therapy of Bone Metastases
por: Fernández, René, et al.
Publicado: (2021)

Dynamic susceptibility contrast MRI may contribute in prediction of stereotactic radiosurgery outcome in brain metastases
por: Starck, Lea, et al.
Publicado: (2022)

Automated detection and quantification of brain metastases on clinical MRI data using artificial neural networks
por: Pflüger, Irada, et al.
Publicado: (2022)

Collagen deposition within brain metastases is associated with leptomeningeal failure after  cavity-directed radiosurgery
por: Abdulhaleem, Mohammed, et al.
Publicado: (2023)

Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases
por: Fischer, Grant M, et al.
Publicado: (2021)

High frequency of brain metastases after adjuvant therapy for high‐risk melanoma
por: Samlowski, Wolfram E., et al.
Publicado: (2017)

Are prognostic indices for brain metastases of melanoma still valid in the stereotactic era?
por: Badakhshi, Harun, et al.
Publicado: (2018)

A Dutch phase III randomized multicenter trial: whole brain radiotherapy versus stereotactic radiotherapy for 4–10 brain metastases
por: Hartgerink, Dianne, et al.
Publicado: (2021)

Targeted Therapies for Melanoma Brain Metastases
por: Berghoff, Anna S., et al.
Publicado: (2017)

Feasibility and safety of cavity-directed stereotactic radiosurgery for brain metastases at a high-volume medical center
por: Rava, Paul, et al.
Publicado: (2016)

Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases
por: Goldstein, Iris M, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_87egosnmeboc8kn2em6si8e5dc